Short fasting dramatically decreases rat duodenal secretory responsiveness to orexin A but not to VIP or melatonin.
Orexins are involved in the central nervous control of appetite and behavior, and in addition, they are present in endocrine cells and/or neurons in the intestine. The role of these peptides in peripheral regulation of intestinal secretion has not been investigated. We thus compared the effects of orexin A and some established secretagogues on duodenal HCO3- secretion in fed rats with effects in rats exposed to short (overnight) food deprivation. Rats were anesthetized with thiobarbiturate, a 12-mm segment of proximal duodenum with intact blood supply was cannulated in situ, and the alkaline secretion was titrated by pH stat. Secretagogues were supplied specifically to the duodenum by close intra-arterial infusion. Orexin A (60-600 pmol x kg(-1) x h(-1)) caused marked and dose-dependent stimulation of the duodenal secretion in fed animals but did not affect secretion in overnight food-deprived animals. Similarly, short fasting caused a 100-fold increase in the amount of the muscarinic agonist bethanechol (from 50 to 5,000 nmol x kg(-1) x h(-1)) required for stimulation of the secretion. In contrast, the secretory responses to VIP (50-1,000 pmol x kg(-1) x h(-1)) and melatonin (20-200 nmol x kg(-1) x h(-1)) were not affected. The appetite-regulating peptide orexin A is thus a stimulant of intestinal secretion, but the response to this peptide as well as the muscarinic agonist bethanechol is markedly dependent on previous intake of food. Overnight fasting is a standard experimental procedure in studies of gastrointestinal function and pathophysiology in humans and animals. Studies made on neuroendocrine control of intestinal secretion may require reevaluation with respect to feeding status.
Flemström
Gunnar
G
Department of Neuroscience, Division of Physiology, Uppsala University, SE-751 23 Uppsala, Sweden. Gunnar.Flemstrom@Fysiologi.uu.se
Sjöblom
Markus
M
Jedstedt
Gunilla
G
Akerman
Karl E O
KE
D000818:Animals; D018723:Bethanechol / Q000494:pharmacology; D002352:Carrier Proteins / Q000494:pharmacology*; D004386:Duodenum / Q000187:drug effects* / Q000378:metabolism*; D005215:Fasting / Q000502:physiology*; D005508:Food Deprivation / Q000502:physiology; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006801:Humans; D007269:Injections, Intra-Arterial; D047908:Intracellular Signaling Peptides and Proteins; D008550:Melatonin / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D018721:Muscarinic Agonists / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D000068797:Orexins; D051381:Rats; D011919:Rats, Inbred Strains; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology*
D002352:Carrier Proteins; D005765:Gastrointestinal Agents; C000596229:HCRT protein, human; D047908:Intracellular Signaling Peptides and Proteins; D018721:Muscarinic Agonists; D009479:Neuropeptides; D000068797:Orexins; D018723:Bethanechol; D014660:Vasoactive Intestinal Peptide; D008550:Melatonin